Drug Type Small molecule drug |
Synonyms DC-806, LY4100504, S 011806 + [1] |
Target |
Action inhibitors |
Mechanism IL-17A inhibitors(Interleukin 17A inhibitors) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
License Organization |
Drug Highest PhaseDiscontinuedPhase 2 |
First Approval Date- |
Regulation- |
Molecular FormulaC33H48FN7O4 |
InChIKeyWEXJUHWVWXUMKQ-GVIAMBBFSA-N |
CAS Registry2467732-66-5 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Psoriasis | Phase 2 | United States | 11 May 2023 | |
Plaque psoriasis | Phase 2 | United States | 02 May 2023 | |
Plaque psoriasis | Phase 2 | Canada | 02 May 2023 | |
Plaque psoriasis | Phase 2 | Czechia | 02 May 2023 | |
Plaque psoriasis | Phase 2 | Germany | 02 May 2023 | |
Plaque psoriasis | Phase 2 | Hungary | 02 May 2023 | |
Plaque psoriasis | Phase 2 | Poland | 02 May 2023 | |
Plaque psoriasis | Phase 2 | Spain | 02 May 2023 | |
Plaque psoriasis | Phase 2 | United Kingdom | 02 May 2023 |
Phase 2 | 229 | Placebo (Placebo) | xuluyjaacf = dwnoalnvmi rjhagdeswt (icxnxcopce, pddvwidpik - nsngydqpnc) View more | - | 04 Apr 2025 | ||
(DC-806 200 mg BID) | xuluyjaacf = oqbdcalyyj rjhagdeswt (icxnxcopce, eegwxvuttr - otrbprkbds) View more | ||||||
Corporate Publications Manual | Phase 1 | 32 | DC-806 200 mg | eebltvpktc(attkxgkodm) = anctaztkci gbwsrsxksb (pzbgrucydq ) View more | Positive | 11 Oct 2022 | |
DC-806 800 mg | eebltvpktc(attkxgkodm) = ugqbdlyqlr gbwsrsxksb (pzbgrucydq ) View more |